As mentioned last week, Lilly was one of only four companies to come forward and speak at the Part 15 meeting held by the FDA last week in Washington to focus on social media and medical product prom0tion on the Internet.
And not only were the one of four, they were also the most comprehensive. In particular, they focused on the fact that new media are emerging at a faster pace than can be regulated by the FDA’s process. I had the chance to chat with Lilly’s presenter for a few minutes. Here is what she had to say.
